PL3148513T3 - Formulacja cerytynibu - Google Patents

Formulacja cerytynibu

Info

Publication number: PL3148513T3
Authority: PL; Poland
Prior art keywords: ceritinib; formulation; ceritinib formulation
Prior art date: 2014-05-29

Application number

PL15727470T

Other languages

English (en)

Inventor

Sebastien BREULLES

Simon Ensslin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-29

Filing date

2015-05-27

Publication date

2020-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3148513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-27 Application filed by Novartis Ag filed Critical Novartis Ag

2020-08-24 Publication of PL3148513T3 publication Critical patent/PL3148513T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cephalosporin Compounds (AREA)

PL15727470T 2014-05-29 2015-05-27 Formulacja cerytynibu PL3148513T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462004359P	2014-05-29	2014-05-29
PCT/IB2015/053966 WO2015181739A1 (en)	2014-05-29	2015-05-27	Ceritinib formulation
EP15727470.5A EP3148513B1 (en)	2014-05-29	2015-05-27	Ceritinib formulation

Publications (1)

Publication Number	Publication Date
PL3148513T3 true PL3148513T3 (pl)	2020-08-24

Family

ID=53298568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15727470T PL3148513T3 (pl)	2014-05-29	2015-05-27	Formulacja cerytynibu

Country Status (27)

Country	Link
US (4)	US20170112834A1 (pl)
EP (1)	EP3148513B1 (pl)
JP (3)	JP6679578B2 (pl)
KR (1)	KR20170008239A (pl)
CN (1)	CN106456640B (pl)
AR (1)	AR100625A1 (pl)
AU (3)	AU2015265470A1 (pl)
BR (1)	BR112016027580A8 (pl)
CA (1)	CA2948291A1 (pl)
CL (1)	CL2016003047A1 (pl)
DK (1)	DK3148513T3 (pl)
EA (1)	EA036922B1 (pl)
EC (1)	ECSP16096826A (pl)
ES (1)	ES2792574T3 (pl)
HU (1)	HUE048950T2 (pl)
IL (1)	IL248835B (pl)
MX (1)	MX373624B (pl)
PE (1)	PE20170313A1 (pl)
PH (1)	PH12016502272A1 (pl)
PL (1)	PL3148513T3 (pl)
PT (1)	PT3148513T (pl)
SG (1)	SG11201609208UA (pl)
SI (1)	SI3148513T1 (pl)
TN (1)	TN2016000484A1 (pl)
TW (1)	TWI721946B (pl)
UY (1)	UY36140A (pl)
WO (1)	WO2015181739A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106176752B (zh) *	2015-05-07	2020-06-23	石药集团中奇制药技术（石家庄）有限公司	色瑞替尼药物组合物
CN109381440A (zh) *	2018-11-15	2019-02-26	威海贯标信息科技有限公司	一种艾乐替尼组合物
CN113244236B (zh) *	2021-06-01	2023-02-03	上海市第一人民医院	色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3632778A (en) *	1970-06-10	1972-01-04	Hoffmann La Roche	Tablets containing l-dopa
US20070208067A1 (en) *	2006-03-06	2007-09-06	Wyeth	Tablet Formulations and Processes
US20090239920A1 (en) *	2006-11-21	2009-09-24	Wyeth	Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) *	2006-11-21	2008-07-24	Wyeth	Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US8039479B2 (en) *	2006-12-08	2011-10-18	Irm Llc	Compounds and compositions as protein kinase inhibitors
MX2009006081A (es) *	2006-12-08	2009-06-17	Irmc Llc	Compuestos y composiciones como inhibidores de cinasa de proteina.
EP2090297A1 (en)	2008-02-13	2009-08-19	Boehringer Ingelheim International GmbH	Formulations of flibanserin
ES2377869T3 (es) *	2008-09-04	2012-04-02	Cargill, Incorporated	FabricaciÃ³n de comprimidos de eritritol
JO3635B1 (ar) *	2009-05-18	2020-08-27	Millennium Pharm Inc	مركبات صيدلانية صلبة وطرق لانتاجها
JP5751677B2 (ja) *	2009-08-18	2015-07-22	カーギルインコーポレイテッド	エリトリトールおよびイソマルトのタブレット化
JP5596799B2 (ja)	2010-05-11	2014-09-24	田辺三菱製薬株式会社	カナグリフロジン含有錠剤
BR112013005440A2 (pt) *	2010-09-07	2016-05-17	Cargill Inc	"mistura de álcool de açúcar solidificada".

2015
- 2015-05-27 PT PT157274705T patent/PT3148513T/pt unknown
- 2015-05-27 TW TW104117053A patent/TWI721946B/zh not_active IP Right Cessation
- 2015-05-27 TN TN2016000484A patent/TN2016000484A1/en unknown
- 2015-05-27 PE PE2016002399A patent/PE20170313A1/es not_active Application Discontinuation
- 2015-05-27 CA CA2948291A patent/CA2948291A1/en not_active Abandoned
- 2015-05-27 SI SI201531221T patent/SI3148513T1/sl unknown
- 2015-05-27 JP JP2017514990A patent/JP6679578B2/ja active Active
- 2015-05-27 EP EP15727470.5A patent/EP3148513B1/en active Active
- 2015-05-27 EA EA201692310A patent/EA036922B1/ru not_active IP Right Cessation
- 2015-05-27 US US15/313,367 patent/US20170112834A1/en not_active Abandoned
- 2015-05-27 BR BR112016027580A patent/BR112016027580A8/pt not_active Application Discontinuation
- 2015-05-27 DK DK15727470.5T patent/DK3148513T3/da active
- 2015-05-27 AU AU2015265470A patent/AU2015265470A1/en not_active Abandoned
- 2015-05-27 AR ARP150101661A patent/AR100625A1/es unknown
- 2015-05-27 UY UY0001036140A patent/UY36140A/es not_active Application Discontinuation
- 2015-05-27 CN CN201580028582.7A patent/CN106456640B/zh active Active
- 2015-05-27 PL PL15727470T patent/PL3148513T3/pl unknown
- 2015-05-27 SG SG11201609208UA patent/SG11201609208UA/en unknown
- 2015-05-27 HU HUE15727470A patent/HUE048950T2/hu unknown
- 2015-05-27 WO PCT/IB2015/053966 patent/WO2015181739A1/en active Application Filing
- 2015-05-27 KR KR1020167032886A patent/KR20170008239A/ko not_active Application Discontinuation
- 2015-05-27 ES ES15727470T patent/ES2792574T3/es active Active
2016
- 2016-11-08 IL IL248835A patent/IL248835B/en active IP Right Grant
- 2016-11-15 PH PH12016502272A patent/PH12016502272A1/en unknown
- 2016-11-28 CL CL2016003047A patent/CL2016003047A1/es unknown
- 2016-11-29 MX MX2016015736A patent/MX373624B/es active IP Right Grant
- 2016-12-28 EC ECIEPI201696826A patent/ECSP16096826A/es unknown
2018
- 2018-05-01 AU AU2018203007A patent/AU2018203007B2/en not_active Ceased
- 2018-09-26 US US16/142,263 patent/US20190022095A1/en not_active Abandoned
2019
- 2019-09-16 US US16/571,229 patent/US11000523B2/en active Active
- 2019-09-20 AU AU2019232937A patent/AU2019232937B2/en not_active Ceased
2020
- 2020-03-17 JP JP2020046475A patent/JP7084955B2/ja active Active
2021
- 2021-02-05 US US17/168,265 patent/US20210154194A1/en active Pending
2022
- 2022-03-08 JP JP2022034913A patent/JP2022078236A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CL2016003047A1 (es)	2017-04-07
PE20170313A1 (es)	2017-04-18
JP2022078236A (ja)	2022-05-24
TWI721946B (zh)	2021-03-21
SG11201609208UA (en)	2016-12-29
IL248835B (en)	2020-05-31
US11000523B2 (en)	2021-05-11
AU2019232937A1 (en)	2019-10-10
ECSP16096826A (es)	2018-04-30
PH12016502272A1 (en)	2017-02-06
JP6679578B2 (ja)	2020-04-15
AU2015265470A1 (en)	2016-11-24
EP3148513B1 (en)	2020-02-26
HUE048950T2 (hu)	2020-09-28
BR112016027580A2 (pt)	2017-08-15
PT3148513T (pt)	2020-05-27
DK3148513T3 (da)	2020-05-25
AU2018203007B2 (en)	2019-07-18
TW201613580A (en)	2016-04-16
MX2016015736A (es)	2017-03-16
CN106456640A (zh)	2017-02-22
BR112016027580A8 (pt)	2021-06-29
JP2017520619A (ja)	2017-07-27
JP2020114834A (ja)	2020-07-30
US20170112834A1 (en)	2017-04-27
AU2019232937B2 (en)	2020-10-15
MX373624B (es)	2025-03-05
ES2792574T3 (es)	2020-11-11
CN106456640B (zh)	2021-05-14
AR100625A1 (es)	2016-10-19
US20200009141A1 (en)	2020-01-09
WO2015181739A1 (en)	2015-12-03
EP3148513A1 (en)	2017-04-05
EA201692310A1 (ru)	2017-04-28
SI3148513T1 (sl)	2020-07-31
EA036922B1 (ru)	2021-01-15
IL248835A0 (en)	2017-01-31
CA2948291A1 (en)	2015-12-03
AU2018203007A1 (en)	2018-05-17
UY36140A (es)	2016-01-08
TN2016000484A1 (en)	2018-04-04
JP7084955B2 (ja)	2022-06-15
US20190022095A1 (en)	2019-01-24
KR20170008239A (ko)	2017-01-23
US20210154194A1 (en)	2021-05-27

Publication	Publication Date	Title
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da)	2021-10-25	Karadgang
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
EP3230438C0 (en)	2024-12-04	N-GLYCOSYLATION
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement
DK3148513T3 (da)	2020-05-25	Ceritinib-formulering
DK3009858T3 (da)	2021-08-09	Skyradar
DK3193856T3 (da)	2021-09-06	Formulering
DE112015001633A5 (de)	2017-02-23	Betätigungsaktuator
DK3447493T3 (da)	2020-08-17	Proteinrettede ortologer
ES1133830Y (es)	2015-02-12	Columbario
DK3091875T3 (da)	2019-10-14	Vipbar taburet
DE202014005655U8 (de)	2014-11-13	llluminationsvorrichtung
DE112015005055A5 (de)	2017-08-03	Gargerätevorrichtung
DK3191825T3 (da)	2019-05-06	Kreatininbiosensor
DE112015004618A5 (de)	2017-09-07	Garnitur
FI10894U1 (fi)	2015-06-11	Putkieristyskouru